» Articles » PMID: 25566497

Pharmacological Doses of Daily Ascorbate Protect Tumors from Radiation Damage After a Single Dose of Radiation in an Intracranial Mouse Glioma Model

Overview
Journal Front Oncol
Specialty Oncology
Date 2015 Jan 8
PMID 25566497
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacological ascorbate is currently used as an anti-cancer treatment, potentially in combination with radiation therapy, by integrative medicine practitioners. In the acidic, metal-rich tumor environment, ascorbate acts as a pro-oxidant, with a mode of action similar to that of ionizing radiation; both treatments kill cells predominantly by free radical-mediated DNA damage. The brain tumor, glioblastoma multiforme (GBM), is very resistant to radiation; radiosensitizing GBM cells will improve survival of GBM patients. Here, we demonstrate that a single fraction (6 Gy) of radiation combined with a 1 h exposure to ascorbate (5 mM) sensitized murine glioma GL261 cells to radiation in survival and colony-forming assays in vitro. In addition, we report the effect of a single fraction (4.5 Gy) of whole brain radiation combined with daily intraperitoneal injections of ascorbate (1 mg/kg) in an intracranial GL261 glioma mouse model. Tumor-bearing C57BL/6 mice were divided into four groups: one group received a single dose of 4.5 Gy to the brain 8 days after tumor implantation, a second group received daily intraperitoneal injections of ascorbate (day 8-45) after implantation, a third group received both treatments and a fourth control group received no treatment. While radiation delayed tumor progression, intraperitoneal ascorbate alone had no effect on tumor progression. Tumor progression was faster in tumor-bearing mice treated with radiation and daily ascorbate than in those treated with radiation alone. Histological analysis showed less necrosis in tumors treated with both radiation and ascorbate, consistent with a radio-protective effect of ascorbate in vivo. Discrepancies between our in vitro and in vivo results may be explained by differences in the tumor microenvironment, which determines whether ascorbate remains outside the cell, acting as a pro-oxidant, or whether it enters the cells and acts as an anti-oxidant.

Citing Articles

Role of Sodium-Dependent Vitamin C Transporter-2 and Ascorbate in Regulating the Hypoxic Pathway in Cultured Glioblastoma Cells.

Burgess E, Praditi C, Phillips E, Vissers M, Robinson B, Dachs G J Cell Biochem. 2024; 126(1):e30658.

PMID: 39382087 PMC: 11729540. DOI: 10.1002/jcb.30658.


Combination of Ascorbic Acid and Menadione Induces Cytotoxic Autophagy in Human Glioblastoma Cells.

Despotovic A, Mircic A, Misirlic-Dencic S, Harhaji-Trajkovic L, Trajkovic V, Zogovic N Oxid Med Cell Longev. 2022; 2022:2998132.

PMID: 35368869 PMC: 8967583. DOI: 10.1155/2022/2998132.


Targeting Glioblastoma via Selective Alteration of Mitochondrial Redox State.

Sumiyoshi A, Shibata S, Zhelev Z, Miller T, Lazarova D, Aoki I Cancers (Basel). 2022; 14(3).

PMID: 35158753 PMC: 8833725. DOI: 10.3390/cancers14030485.


High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer.

Bottger F, Valles-Marti A, Cahn L, Jimenez C J Exp Clin Cancer Res. 2021; 40(1):343.

PMID: 34717701 PMC: 8557029. DOI: 10.1186/s13046-021-02134-y.


The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response.

Crake R, Burgess E, Royds J, Phillips E, Vissers M, Dachs G Front Oncol. 2021; 11:619300.

PMID: 33842321 PMC: 8027507. DOI: 10.3389/fonc.2021.619300.


References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Newcomb E, Lukyanov Y, Kawashima N, Alonso-Basanta M, Wang S, Liu M . Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res. 2010; 173(4):426-32. PMC: 3721320. DOI: 10.1667/RR1904.1. View

3.
Felipe K, Benites J, Glorieux C, Sid B, Valenzuela M, Kviecinski M . Antiproliferative effects of phenylaminonaphthoquinones are increased by ascorbate and associated with the appearance of a senescent phenotype in human bladder cancer cells. Biochem Biophys Res Commun. 2013; 433(4):573-8. DOI: 10.1016/j.bbrc.2013.03.028. View

4.
Larson E, Peterson H, Lamoreaux W, Mackay A, Fairbanks R, Call J . Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma. World J Clin Oncol. 2014; 5(2):142-8. PMC: 4014786. DOI: 10.5306/wjco.v5.i2.142. View

5.
Facchino S, Abdouh M, Chatoo W, Bernier G . BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010; 30(30):10096-111. PMC: 6633363. DOI: 10.1523/JNEUROSCI.1634-10.2010. View